QIAGEN N.V. QGEN

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS1.94

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.09B$1.98B$1.97B$2.14B$2.25B$1.87B$1.53B$1.50B$1.42B$1.34B
Cost of revenue $790.5M$1.01B$731.6M$757.0M$800.8M$637.6M$521.2M$500.9M$495.0M$493.3M
Gross profit $1.30B$967.4M$1.23B$1.38B$1.45B$1.23B$1.01B$1.00B$922.6M$844.7M
SG&A $125.7M$113.4M$119.3M$129.7M$128.1M$111.7M$112.3M$104.6M$102.1M—
Total operating expenses $833.6M$869.6M$823.8M$853.1M$820.7M$846.3M$1.03B$734.4M$769.1M$745.8M
Operating income $465.9M$97.7M$409.9M$531.5M$630.1M$386.4M-$26.1M$266.6M$153.4M$98.8M
Interest expense $33.3M$43.8M$53.4M$58.4M$54.5M$71.3M$74.2M$67.3M$49.7M$39.0M
Pre-tax income $490.3M$121.1M$429.8M$512.6M$625.8M$439.5M-$77.8M$225.7M$114.4M$56.9M
Income tax $65.4M$37.6M$88.5M$89.4M$113.2M$80.3M$36.3M$35.4M$74.0M$23.4M
Net income $424.9M$83.6M$341.3M$423.2M$512.6M$359.2M-$41.5M$190.4M$40.4M$80.4M
EPS, basic 1.960.381.501.862.251.57-0.180.840.180.34
EPS, diluted 1.940.371.481.842.211.53-0.180.820.170.34
Shares, diluted (wtd. avg.) 218.9M224.7M230.6M230.1M232.0M234.2M226.8M233.5M233.0M239.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $839.0M$663.6M$668.1M$730.7M$880.5M$598.0M$629.4M$1.16B$657.7M$439.2M
Short-term investments $259.9M$489.4M$389.7M$687.6M$184.8M$117.2M$129.6M$234.6M$359.2M$93.0M
Receivables $402.6M$349.3M$381.9M$323.8M$362.1M$380.5M$385.1M$351.6M$329.1M$278.2M
Inventory $301.9M$279.3M$398.4M$358.0M$327.5M$291.2M$170.7M$162.9M$155.9M$136.6M
Total current assets $2.00B$1.96B$2.15B$2.39B$2.11B$1.62B$1.57B$2.16B$1.65B$1.04B
Property, plant and equipment $923.9M$753.6M$765.0M$662.2M$638.2M$559.4M$455.2M$511.7M$494.3M$436.7M
Goodwill $2.70B$2.43B$2.48B$2.35B$2.35B$2.36B$2.14B$2.11B$2.01B$1.93B
Other intangibles $386.4M$303.8M$526.8M$544.8M$627.4M$726.2M$632.4M$475.0M$499.3M$557.2M
Total assets $6.28B$5.69B$6.12B$6.29B$6.15B$5.87B$5.24B$5.75B$5.04B$4.31B
Accounts payable $72.7M$83.3M$84.2M$98.7M$101.2M$118.2M$84.8M$69.4M$59.2M$51.2M
Short-term debt $0$551.9M$588.0M$389.6M$847.6M$42.5M$285.2M$503.1M$0—
Total current liabilities $512.1M$1.04B$1.08B$974.5M$1.52B$572.2M$951.3M$972.2M$324.8M$308.4M
Long-term debt $1.65B$839.7M$921.8M$1.47B$1.09B$1.88B$1.42B$1.67B$1.76B$1.07B
Retained earnings $2.75B$2.45B$2.46B$2.16B$1.79B$1.32B$1.18B$1.38B$1.25B$1.26B
Total equity $3.78B$3.57B$3.81B$3.47B$3.10B$2.80B$2.54B$2.63B$2.54B$2.61B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $654.3M$673.6M$459.5M$715.3M$639.0M$457.8M$330.8M$359.5M$286.8M$341.6M
Depreciation and amortisation $193.7M$203.3M$205.3M$208.4M$214.9M$205.0M$231.5M$206.4M$216.4M$213.1M
Stock-based compensation $50.4M$43.6M$47.1M$49.5M$38.4M$40.9M$65.9M$40.1M$34.4M$28.3M
Capital expenditure $201.0M$167.2M$149.7M$129.2M$189.9M$132.8M$118.0M$109.8M$90.1M$74.5M
Investing cash flow -$305.3M-$249.2M-$87.7M-$726.8M-$202.4M-$443.3M-$222.3M-$211.4M-$464.3M-$179.1M
Financing cash flow -$179.0M-$422.9M-$433.8M-$125.8M-$150.4M-$50.1M-$639.1M$360.4M$387.2M-$10.6M
Dividends paid $54.2M$0$0———————
Buybacks $280.1M$292.1M$0$0$100.0M$64.0M$74.5M$104.7M$61.0M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001015820-26-000018.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B Revenue, FY2016: 1.3B Gross profit, FY2016: 844.7M Net income, FY2016: 80.4M Revenue, FY2017: 1.4B Gross profit, FY2017: 922.6M Net income, FY2017: 40.4M Revenue, FY2018: 1.5B Gross profit, FY2018: 1B Net income, FY2018: 190.4M Revenue, FY2019: 1.5B Gross profit, FY2019: 1B Net income, FY2019: -41.5M Revenue, FY2020: 1.9B Gross profit, FY2020: 1.2B Net income, FY2020: 359.2M Revenue, FY2021: 2.3B Gross profit, FY2021: 1.5B Net income, FY2021: 512.6M Revenue, FY2022: 2.1B Gross profit, FY2022: 1.4B Net income, FY2022: 423.2M Revenue, FY2023: 2B Gross profit, FY2023: 1.2B Net income, FY2023: 341.3M Revenue, FY2024: 2B Gross profit, FY2024: 967.4M Net income, FY2024: 83.6M Revenue, FY2025: 2.1B Gross profit, FY2025: 1.3B Net income, FY2025: 424.9M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $1.34B $1.42B $1.50B $1.53B $1.87B $2.25B $2.14B $1.97B $1.98B $2.09B
Gross profit $844.7M $922.6M $1.00B $1.01B $1.23B $1.45B $1.38B $1.23B $967.4M $1.30B
Net income $80.4M $40.4M $190.4M -$41.5M $359.2M $512.6M $423.2M $341.3M $83.6M $424.9M

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%